Robert Francomano
No más puestos en curso
Fortuna: 36 355 $ al 30/04/2024
Perfil
Robert M.
Francomano served as the Chief Commercial Officer at Stemline Therapeutics, Inc. from 2016 to 2021.
He then held the position of Chief Commercial Officer & Senior Vice President at SELLAS Life Sciences Group, Inc. from 2022 to 2024.
Prior to his roles in the pharmaceutical industry, he obtained an undergraduate degree from Siena College and an MBA from the University of Albany.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
22/01/2024 | 23 918 ( 0.04% ) | 36 355 $ | 30/04/2024 |
Antiguos cargos conocidos de Robert Francomano.
Empresas | Cargo | Fin |
---|---|---|
SELLAS LIFE SCIENCES GROUP, INC. | Corporate Officer/Principal | 31/03/2024 |
STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/12/2021 |
Formación de Robert Francomano.
Siena College | Undergraduate Degree |
University of Albany | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
SELLAS LIFE SCIENCES GROUP, INC. | Health Technology |
Empresas privadas | 1 |
---|---|
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
- Bolsa de valores
- Insiders
- Robert Francomano